Business
Abacus Global Management buys life insurance policies and manages life-settlement assets, with Life Solutions as the largest disclosed product/service line in FY2025.
Abacus Global more than doubled revenue and swung to profit, but free cash flow stayed negative.
The read at a glance✓ Audited against SEC data
- Business mix — Life settlement buyer and asset managerNote
- Growth — Revenue +110.2% to $235MOK
- Profitability — Net income swung to $36.5M profitOK
- Cash quality — Free cash flow still -$26.6MWatch
- Capital — Buybacks +307.6% to $43.8MWatch
- Balance sheet — Debt +6.6% to $406MWatch
- Accounting — Altman-Z distress; fair-value audit focusWatch
Where the revenue comes from
Fiscal 2025, as Abacus Global Management, Inc. reports it. History and quarterly detail are in the app.
- Life solutions$200.7M
- Asset Management1$29.7M
- Technology services$717K
Leadership changes
From Abacus Global Management, Inc.'s own filings, the day they're filed.
- Sean McNealy · director · departureeff. 2026-06-30
- Alexei Solomon · Chief Accounting Officer · appointmenteff. 2026-04-17
- William McCauley · Chief Financial Officer · appointmenteff. 2026-03-12
Latest filings
- 8-K · Company announcement2026-08-24
- 8-K · Company announcement2026-08-13
- 10-Q · Quarterly report2026-08-10
- 8-K · Company announcement2026-08-06
- 8-K · Company announcement2026-07-02
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- Main tension🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about Abacus Global Management, Inc., every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.